title: Cabozantinib in genitourinary malignancies.
abstract: Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.
authors.affiliation: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Tian
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Se Eun
authors.initials: SE
authors.lastname: Park
authors.affiliation: Duke University School of Medicine, Durham, NC 27710, USA.
authors.forename: Cierra
authors.initials: C
authors.lastname: Hong
authors.affiliation: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.|Division of Urology, Departments of Medicine & Surgery, Duke Cancer Institute, Duke University Medical Center, DUMC 103861, Durham, NC 27710, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
mesh_terms: D000813:Anilides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014565:Urogenital Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C558660:cabozantinib
keywords: cabozantinib; genitourinary malignancies; renal cell carcinoma